You completed the intake, waited for the physician review, and got the message nobody wants: your GLP-1 prescription request was denied. Before you assume it's over, understand that denials are common, often fixable, and sometimes just require a different approach. Here are the five most common reasons — and what to do about each one.
1. BMI Below the Prescribing Threshold
The FDA-approved indications for semaglutide (Wegovy) and tirzepatide (Zepbound) require a BMI of 30+ (obesity), or BMI of 27+ with at least one weight-related comorbidity — hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.
If your BMI is 26 and you have no documented comorbidities, most telehealth providers cannot prescribe. This isn't arbitrary gatekeeping — it's FDA label compliance and medical liability management.
What to do: If you're close to the threshold, check whether you have any documented comorbidities that qualify. Prediabetes (A1C 5.7–6.4%), borderline hypertension, or elevated triglycerides may satisfy the 27+ BMI pathway. Request your recent lab work from your PCP and resubmit with documented comorbidities.
2. Contraindicated Medical History
GLP-1 receptor agonists carry specific contraindications. A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) is an absolute contraindication. Active or recent pancreatitis is another. History of gastroparesis or severe gastrointestinal disease may also result in denial, depending on the provider's clinical judgment.
What to do: If you were denied for a family history concern, clarify the specifics. A family member with general thyroid cancer (papillary or follicular) is not the same as MTC. Many patients and even some intake forms conflate these. If you were denied for GI history, a letter from your gastroenterologist clearing you for GLP-1 therapy may resolve the issue.
Common Misunderstanding
General thyroid cancer in a family member does NOT trigger the MTC/MEN2 contraindication. Only medullary thyroid carcinoma — a specific, rare subtype — is contraindicated. If you were denied based on a misidentified thyroid cancer type, request clarification and resubmit.
3. Drug Interactions
GLP-1 medications have relatively few hard drug interactions, but insulin and sulfonylureas are the most common flags. If you're on insulin, starting a GLP-1 requires careful dose adjustment to avoid hypoglycemia. Some telehealth platforms aren't equipped for this level of diabetes co-management and may deny rather than take on the complexity.
What to do: If denied due to insulin or sulfonylurea use, look for providers that specialize in GLP-1 therapy for diabetic patients. These platforms have physicians experienced in adjusting insulin doses concurrently. Alternatively, ask your endocrinologist to manage the GLP-1 initiation and handle the insulin titration.
4. Incomplete or Inconsistent Intake Information
This is the most fixable denial reason — and it's more common than you'd think. Leaving fields blank, providing inconsistent medication information, or failing to disclose relevant medical history triggers a review flag that many providers resolve by denying rather than following up.
What to do: Resubmit with complete, accurate information. Have your medication list ready (names, doses, frequency). Disclose all conditions, including mental health diagnoses. If you take supplements, list them — some interact with GLP-1 absorption timing.
5. Insurance Prior Authorization Failure (Brand-Name Only)
If you requested brand-name Wegovy or Zepbound through insurance, your prescription may have been denied at the prior authorization stage — not by the prescribing physician, but by your insurance company. Prior authorization denial rates for GLP-1 medications range from 30–60% on first submission depending on the insurer.
What to do: You have three options. First, appeal — ask your prescriber to submit a peer-to-peer review with the insurer. Second, switch to compounded medication, which bypasses insurance entirely and costs $146–300/month out-of-pocket. Third, try Eli Lilly's direct-to-consumer program (LillyDirect) for Zepbound at $399/month without insurance.
Don't give up after one denial. Most telehealth GLP-1 denials are procedural, not medical. About 70% of patients who are denied on the first attempt can qualify by correcting their intake, clarifying their medical history, or trying a different provider with different clinical criteria.
Try a Different Provider
All providers are US-licensed telehealth platforms. State availability varies.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚠️ Disclosure: MEDVi received an FDA warning letter in February 2026 regarding product misbranding. Consumers should review this information before enrolling.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
When a Denial Is Medically Appropriate
Not every denial should be appealed. If you have a genuine MTC/MEN2 contraindication, active pancreatitis, or are pregnant or planning pregnancy, GLP-1 medications are not safe for you. A responsible provider protecting you from harm is doing their job. In these cases, discuss alternative weight-management approaches with your primary care physician.
Sources & References
- FDA. Wegovy (semaglutide) Prescribing Information. Contraindications section.
- FDA. Zepbound (tirzepatide) Prescribing Information. Contraindications section.
- KFF Health Insurance Survey. Prior Authorization Denial Rates for Obesity Medications. 2025.
- Eli Lilly. LillyDirect Zepbound Program. $399/month pricing. 2025–2026.
- AMA. Prior Authorization Reform Principles. 2024.